SEC Form 4 · accession 0001615774-18-014475
Emmaus Life Sciences, Inc. · EMMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick Herguth
Officer — Chief Executive Officer
Period of report
Dec 12, 2018
Accepted (ET)
Dec 14, 2018 · 4:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822370
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EMPLOYEE STOCK OPTION (right to purchase)F1 | $1.28 | Dec 12, 2018 | A | 400,000 | A | Dec 12, 2018 | Dec 12, 2028 | Common Stock | 400,000 | 400,000 | D |
Explanation of responses
- F1On December 12, 2018, the Reporting Person was granted an option to purchase 400,000 shares of common stock. Options to purchase 200,000 of such shares were issued under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan, pursuant to an Employment Agreement, dated as of December 12, 2018, by and between the Company and the Reporting Person. 50,000 of the 400,000 options vested on the grant date, with the remainder vesting upon the satisfaction of performance targets or time-based vesting schedules specified in the Employment Agreement.